hotspot -WSS

hotspot

author：entertainment 2025-09-03 11:50:04 - browse：91447

Scientist pipetting in a biotech lab -- biotech coverage from STAT — A researcher working in the lab at Crinetics Pharmaceuticals in San Diego. Courtesy Crinetics

SAN DIEGO — Crinetics Pharmaceuticals announced on Sunday that its experimental drug for acromegaly, a rare and serious hormonal disorder, succeeded in a late-stage trial, bringing the San Diego biotech a step closer to applying for Food and Drug Administration approval — and entry into a crowded market with blockbuster therapies sold by pharma giants.

In the Phase 3 study, dubbed PATHFNDR-1, nearly 60 patients were randomly assigned to receive a placebo or a daily dose of paltusotine, an oral medicine designed to lower levels of growth hormone, which is produced in excess by people with acromegaly. After 36 weeks of treatment, 25 of the 30 patients given the drug had growth-factor levels that were within the normal range compared to just 1 of 28 participants who took the placebo, a difference that was statistically significant. Researchers also found that the treatment’s side effects were mild overall.

Crinetics plans to file for FDA approval if it gets positive results from a second, ongoing Phase 3 trial of the drug in acromegaly patients. The biotech expects results from that study, known as PATHFNDR-2, by the first quarter of next year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： New research casts further doubt on a common procedure used with IVF

entertainment

WSS

N.Y. state detects polio case, first in the U.S. since 2013

Patients, digital health players weigh in on FTC's data privacy plan

Study: Pain burden is higher in Black NFL players than white ones

Biogen’s boardroom scandal saddles CEO with first crisis

After Optum profits sink, UnitedHealth makes changes

N.Y. state detects polio case, first in the U.S. since 2013

leisure time

hotspot

Wikipedia

Hepatitis C has a cure — but many Americans still lack access to it

Timeline: How the deadly wildfires took over Maui day by day

The cancer drug shortage isn’t new — and neither are the solutions

Hospitals are dialing back on venture capital investing

Hepatitis C has a cure — but many Americans still lack access to it

Be careful with at

In Memoriam: Notable people who died in 2023

Treatments for cramps don't cut it. Why aren't there better options?

Medical leaders decry Supreme Court decision on affirmative action

Living with Fabry disease, a condition that causes chronic pain

focus

BMS, looking to build heart drug business, turns to AI for diagnosis

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

Elizabeth Holmes on track for early release from her 11

Surge in Apellis stock fueled by confidence in safety of its eye drug

Be careful with at

focus

entertainment

entertainment

focus